MAIA clinical study results with DARZALEX® + Rd
How the MAIA study was set up
DARZALEX® was studied in combination with lenalidomide and dexamethasone (DARZALEX® + Rd), compared with Rd alone.
Your treatment goals may be similar to results shown in clinical studies. Here’s a look at what other people were able to achieve with ongoing DARZALEX® + Rd treatment.
Who took part in the study?
737
people total participated in the study
368
people were treated with DARZALEX® + Rd
369
people were treated with Rd alone
What were the goals of the clinical study?
People had newly diagnosed multiple myeloma and could not receive a stem cell transplant that uses their own stem cells. The main goal was to measure how long patients lived without their disease getting worse, or passing away. Another goal was to measure how well people responded to treatment and for how long.
The study was continued to see the ongoing results of DARZALEX® + Rd over time.
A commitment to ongoing treatment with DARZALEX® + Rd until disease progression is supported through MAIA trial results
Response is used to measure how well multiple myeloma cells in your body are being controlled by therapy. As a response deepens (or gets better), fewer cancer cells remain.
You can have a partial response, a very good partial response, or a complete response or better.
Complete response means that you have responded to treatment; there are no signs of cancer seen in imaging, blood, or bone marrow tests.
Original MAIA Study (median 28-month follow-up)
More people lived progression-free*
74%
of people (271 out of 368) in the DARZALEX® + Rd group lived without their disease getting worse or passing away
vs 61% (226 out of 369) treated with Rd alone.
7.1%
of people in the DARZALEX® + Rd group had adverse events that led to discontinuation
vs 15.9% treated with Rd alone.
*Disease progression refers to the length of time a patient lived without having their disease getting worse, or passing away.
Rd=lenalidomide (R) + dexamethasone (d).
More people responded to treatment
93%
~9/10 people (342 out of 368) responded to DARZALEX® + Rd
vs 81% (300 out of 369) people treated with Rd alone.
Based on the overall response rate seen in the primary analysis, 48% of people achieved a complete response or better by staying with DARZALEX® + Rd vs 25% (Rd alone). Those who achieved a complete response or better had a deeper response over time.
Long-term data (5-year follow-up)
More people were still alive
67%
of people were estimated to still be alive after 5 years in the DARZALEX® + Rd group
vs 54% treated with Rd alone.